Submitted by web@researchtop... on Wed, 11/28/2012 - 12:24
iJournal Club - Breast Cancer: 2012
iJournal Club is a unique CME activity that attempts to distill the overwhelming number of important publications and conference presentations in breast cancer in 2012 into a convenient summary of the most clinically relevant papers. Featuring commentary from Drs Harold J Burstein and Charles E Geyer Jr.
HER2-Targeted Therapy
- Primary results from EMILIA
- Response to anti-HER2 therapy after treatment with T-DM1
- Activity of pertuzumab monotherapy and trastuzumab reintroduction
- Should we abandon anthracyclines in the adjuvant setting?
- Results of Phase III NeoALTTO trial
- Risk of rash with pertuzumab
- Effect of adjuvant trastuzumab on outcomes in the metastatic setting
- Results of the Phase II NeoSphere trial
- NSABP-B-41: Lapatinib as a component of neoadjuvant therapy